Scarica l'app Stockscreener
31.80
2.09%
-0.68
Dopo l'orario di chiusura:
31.80
Precedente Chiudi:
$32.48
Aprire:
$32.82
Volume 24 ore:
574.12K
Relative Volume:
0.57
Capitalizzazione di mercato:
$1.90B
Reddito:
$66.05M
Utile/perdita netta:
$-422.60M
Rapporto P/E:
-4.3856
EPS:
-7.251
Flusso di cassa netto:
$-384.73M
1 W Prestazione:
-2.39%
1M Prestazione:
-6.83%
6M Prestazione:
-9.66%
1 anno Prestazione:
-20.36%
Intervallo 1D:
$31.65
$32.82
Intervallo di 1 settimana:
$31.65
$34.12
Portata 52W:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Nome
Agios Pharmaceuticals Inc
Settore
Industria
Telefono
617-649-8600
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
31.80 | 1.95B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-20 | Reiterato | H.C. Wainwright | Buy |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-20 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-27 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Iniziato | Piper Sandler | Overweight |
| 2022-11-17 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-02-15 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Iniziato | Leerink Partners | Mkt Perform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-04-11 | Reiterato | Credit Suisse | Outperform |
| 2018-02-15 | Reiterato | Needham | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-08-10 | Reiterato | Needham | Buy |
| 2017-08-08 | Reiterato | SunTrust | Buy |
| 2017-08-02 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Downgrade | Janney | Buy → Neutral |
| 2017-01-17 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Iniziato | Needham | Buy |
| 2016-06-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Reiterato | SunTrust | Buy |
Mostra tutto
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
How (AGIO) Movements Inform Risk Allocation Models - Stock Traders Daily
Sickle Cell Disease Market Analysis 2036: Industry Trends, Market Size, and Emerging Therapeutic Developments – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma - Barchart.com
AGIO Stock Hits Over 7-Month Highs – FDA Catalyst, ‘Seasonally Strong’ Q2 Earnings Estimate Drive Optimism - Stocktwits
Agios Pharmaceuticals, Inc. (AGIO) Investor Outlook: A 36% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate - Eastern Progress
AGIO Maintained by B of A Securities -- Price Target Raised to $50 - GuruFocus
AGIOS PHARMACEUTICALS, INC. : BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $50 FROM $46 - Bitget
Agios Pharmaceuticals Stock (AGIO) Opinions on Trading Strategies - Quiver Quantitative
Avoiding Lag: Real-Time Signals in (AGIO) Movement - Stock Traders Daily
Agios (AGIO) Momentum: Loses 1.36% to Close at $32.64 in Latest Trading; Boundary Watch: the Session Ends Within the Reported Technical Boundaries at the CloseInvestment Factor - careplusvn.com
Bank of America Corp DE Sells 31,441 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel (NASDAQ:AGIO) - Seeking Alpha
Agios (AGIO) Earnings Report: Profit Per Share Surpasses Its Benchmark; Investor Response: Shares Finish 2.29% Higher in the Latest SessionHealthcare Earnings Report - careplusvn.com
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate - Moomoo
Agios Pharmaceuticals (AGIO) Could Be 24% Undervalued On PYRUKYND Growth Hopes - Sahm
612,850 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by SCS Capital Management LLC - MarketBeat
Q4 2025 Agios Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc.AGIO - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Agios Pharmaceuticals, Inc. (AGIO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Agios Pharmaceuticals, Inc. (AGIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Agios Pharmaceuticals (AGIO) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Agios Pharmaceuticals, Inc. (AGIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sei Investments Co. Acquires 49,198 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Responsive Playbooks and the AGIO Inflection - Stock Traders Daily
FARALLON CAPITAL MANAGEMENT LLC Adds to Agios Pharmaceuticals In - GuruFocus
Agios Pharmaceuticals (AGIO) In Focus On Earnings As Undervalued Narrative Holds - Sahm
AGIO Maintained by JP Morgan -- Price Target Raised to $34 - GuruFocus
Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Raised to $34.00 at JPMorgan Chase & Co. - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Agios Pharmaceuticals, Inc. (AGIO) And Encourages Investors to Connect - ACCESS Newswire
Agios Pharmaceuticals (AGIO) Chief Medical Officer Sarah Gheuens Sells 30,000 Shares - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Agios Pharmaceuticals, Inc. (AGIO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 30,000 Shares - MarketBeat
Agios Pharmaceuticals (AGIO) CMO sells 30,000 shares in plan trade - Stock Titan
How Surging Revenue With Ongoing Losses Will Impact Agios Pharmaceuticals (AGIO) Investors - simplywall.st
AGIO (NASDAQ: AGIO) insider Sarah Gheuens files to sell 30,000 shares - stocktitan.net
Dimensional Fund Advisors LP Increases Position in Agios Pharmaceuticals, Inc. $AGIO - marketbeat.com
Agios Pharmaceuticals (AGIO) Stock Analysis: High Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Farallon Capital (AGIO) discloses 5.9M-share, 9.9% position in Agios - Stock Titan
Seven Fleet Capital Management LP Has $7.09 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Arrowstreet Capital Limited Partnership Makes New Investment in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Agios Pharmaceuticals, Inc. (AGIO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Price to sales forward of Agios Pharmaceuticals, Inc. – NASDAQ:AGIO - TradingView
Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $39 - Moomoo
A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $39 to $55 - Moomoo
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year - Yahoo Finance
AGIO: Q2 2026 delivered $44.7M revenue, strong AQVESME launch, and pipeline progress with ~$1B cash - TradingView
Agios Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Agios Pharmaceuticals reports $44.7M Q2 product revenue, $100.7M net loss, $964.8M cash - TradingView
Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):